
Results
9
Companies that has zero debt on their balance sheet and is forecast to grow at an exponential rate in the future.
9 companies
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: US$124.4b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
SKBH.F
US$50.16
7D
0%
1Y
n/a
Praxis Precision Medicines
Market Cap: US$10.8b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$368.46
7D
-0.5%
1Y
672.5%
Camurus
Market Cap: US$37.8b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMR.F
US$58.51
7D
0%
1Y
n/a
BioArctic
Market Cap: US$29.0b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BRCT.F
US$31.78
7D
0%
1Y
28.2%
Zymeworks
Market Cap: US$1.8b
A biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.
ZYME
US$25.76
7D
11.4%
1Y
80.1%
Bonesupport Holding
Market Cap: US$14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BOEU.F
US$22.94
7D
12.0%
1Y
-28.3%
CARsgen Therapeutics Holdings
Market Cap: US$9.2b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
CRTH.F
US$1.62
7D
-15.6%
1Y
n/a
BioPorto
Market Cap: US$524.8m
An in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia.
THOX.F
US$0.15
7D
0%
1Y
n/a
Marker Therapeutics
Market Cap: US$18.5m
A clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
MRKR
US$1.11
7D
-0.9%
1Y
-11.2%